BICARA THERAPEUTICS INC
BCAXNASDAQTrading Snapshot
- Day Range
- $23.52 – $23.98
- 52-Week Range
- $9.57 – $30.99
- Volume
- $2.24B
- Avg Volume
- $1.57B
- Shares Outstanding
- 65.7M
- Next Earnings
- Sep 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $153M
- Last Q Revenue
- $38M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-2.77
- Dividend Yield
- —
Why Investors Own BCAX
- ✓High-growth profile — revenue up +7.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 68% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BICARA THERAPEUTICS INC
A company profile for BICARA THERAPEUTICS INC isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript
Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call August 11, 2026 8:30 AM EDTCompany ParticipantsRachel Frank - Vice President of Investor Relations and...
Bicara Therapeutics Q2 EPS $(0.82) Beats $(0.84) Estimate
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.84) by 2.38 percent. This is a 64 percent decrease over losses of $(0.50) per share from
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report second quarter 2026 financial results and business updates before the market opens on Tuesday, August 11, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may
Top movers in Friday's after hours session
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 91.1% to $6.04 during Friday's after-market session. The company's market cap stands at $2.2 million. BGM Group (NASDAQ:BGM) stock rose 11.63%
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the appointments of Jeremy Bender, Ph.D., MBA and Christy Oliger to its Board of Directors. Dr. Bender, who most recently served as Chief Executive Officer at Day One Biopharmaceuticals through its acquisition by Servier in 2026, brings more than 20 years of corporat